A hybrid transmission model for Plasmodium vivax accounting for superinfection, immunity and the hypnozoite reservoir (2208.10403v1)

Abstract: Malaria is a vector-borne disease that exacts a grave toll in the Global South. The epidemiology of Plasmodium vivax, the most geographically expansive agent of human malaria, is characterised by the accrual of a reservoir of dormant parasites known as hypnozoites. Relapses, arising from hypnozoite activation events, comprise the majority of the blood-stage infection burden, with implications for the acquisition of immunity and the distribution of superinfection. Here, we construct a hybrid transmission model for P. vivax that concurrently accounts for the accrual of the hypnozoite reservoir, (blood-stage) superinfection and the acquisition of immunity. We begin by analytically characterising within-host dynamics as a function of mosquito-to-human transmission intensity, extending our previous model (comprising an open network of infinite server queues) to capture a discretised immunity level. To model transmission-blocking and antidisease immunity, we allow for geometric decay in the respective probabilities of successful human-to-mosquito transmission and symptomatic blood-stage infection as a function of this immunity level. Under a hybrid approximation -- whereby probabilistic within-host distributions are cast as expected population-level proportions -- we couple host and vector dynamics to recover a deterministic compartmental model in line with Ross-Macdonald theory. We then perform a steady-state analysis for this compartmental model, informed by the (analytic) distributions derived at the within-host level. To characterise transient dynamics, we derive a reduced system of integrodifferential equations (IDEs), likewise informed by our within-host queueing network, allowing us to recover population-level distributions for various quantities of epidemiological interest. Our model provides insights into important, but poorly understood, epidemiological features of P. vivax.